Effects of naloxegol on whole gut transit in opioid‐naïve healthy subjects receiving codeine: A randomized, controlled trial

• Published in: Neurogastroenterology and motility Vol. 30; no. 5; pp. e13298 - n/a
• Main Authors: Halawi, H., Vijayvargiya, P., Busciglio, I., Oduyebo, I., Khemani, D., Ryks, M., Rhoten, D., Burton, D., Szarka, L. A., Acosta, A., Camilleri, M.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2018
• Subjects: Adult; Codeine; Codeine - pharmacology; Colon; Constipation; Double-Blind Method; Female; Gastric emptying; Gastric Emptying - drug effects; Gastrointestinal Transit - drug effects; gastroparesis; Healthy Volunteers; Humans; Male; Middle Aged; Morphinans - pharmacology; Narcotic Antagonists - pharmacology; Narcotics; Narcotics - pharmacology; Nausea; opioid; Opioid receptors (type mu); PAMORA; Polyethylene Glycols - pharmacology; Receptors, Opioid, mu - antagonists & inhibitors; Small intestine; Treatment Outcome; Vomiting; Young Adult; codeine; constipation; PAMORA; gastroparesis; opioid

Background Nausea, vomiting, and constipation (OIC) are common adverse effects of acute or chronic opioid use. Naloxegol (25 mg) is an approved peripherally active mu‐opiate opioid receptor antagonist. Aim To compare the effects on pan‐gut transit of treatment with codeine, naloxegol, or combination...